The Ketogenic Diet: An Unrivaled Approach to Combating Alzheimer’s Disease
Estimated reading time: 34 minutes
Author’s note: As a Licensed Mental Health Counselor with 16 years of private practice experience, I’ve spent the last six years transitioning individuals with mental illness and neurological disorders onto a ketogenic diet. It took me a long time to write this article, and I am not sure why. I think, as someone who suffered from cognitive impairment in my personal health history, this post felt emotional and difficult to be objective about. I didn’t have Alzheimer’s disease (thank goodness), but I did have the cognitive impairment of someone with Stage 1 Alzheimer’s disease. Also, as a mental health counselor, I sit with patients who are watching their loved ones slip away from them due to this illness. The research is much farther ahead on this topic than it was in September 2021 when I began this blog. So much so that I feel quite confident in the strong assertion I have made in the creation of the title “The Ketogenic Diet: An Unrivaled Approach to Combating Alzheimer’s Disease.” And now, something deep in my gut tells me it is time. I write this blog article in the hopes that someone (like you) will find it and learn of a powerful way to markedly slow or stop the disease progression of this illness for themselves or someone they love.
I am not going to go into what Alzheimer’s disease is or its prevalence rates. If you are visiting this post, you are likely here to learn about better treatment options, and time is of the essence. Neurodegenerative processes like dementia are time-sensitive conditions. The longer you wait to treat underlying causes, the more damage is done. Nonetheless, it’s important first to get a handle on existing treatments and their shortcomings. This knowledge will allow you to contrast them with the potential advantages of the ketogenic diet to you or your loved ones.
Current treatment options for Alzheimer’s are nothing short of bleak. Currently approved medications – typically cholinesterase inhibitors and NMDA receptor antagonists – mainly aim to manage the symptoms rather than address the underlying disease mechanisms driving the neurodegenerative process.
Cholinesterase inhibitors such as Donepezil (Aricept), Rivastigmine (Exelon), and Galantamine (Razadyne). These drugs work by slowing down the breakdown of acetylcholine, a neurotransmitter involved in memory and cognition, which is often depleted in Alzheimer’s patients. Common side effects can include nausea, vomiting, and diarrhea.
NMDA receptor antagonists like Memantine (Namenda). This drug works by regulating the activity of glutamate, another neurotransmitter that plays a role in memory and learning. Overactivity of glutamate can cause cellular damage, which Memantine attempts to help to prevent. Potential side effects include dizziness, headaches, and confusion.
While these medications can provide temporary relief for some symptoms like memory disturbances and confusion, they often fall woefully short in halting or even slowing the disease’s progression. Moreover, these drugs come with a litany of potential side effects, ranging from nausea and diarrhea to serious heart rhythm disturbances.
But what about the promise of anti-amyloid beta (Aβ) drugs? These have been promised as the cure, and if we hold out a little bit longer, this miracle drug is going to fix Alzheimer’s disease. Right?
These drugs compromise long-term brain health. So why in the world would we be using this for Alzheimer’s disease? And why are neurologists not providing adequate informed consent to patients about the limitations and dangers of using drugs to attempt to treat the symptoms of Alzheimer’s disease? In our bid to temporarily ease the symptoms, we may inadvertently exacerbate the overall disease trajectory.
In the following sections, we’ll delve deeper into the pathological processes underlying Alzheimer’s disease and explore how a ketogenic diet might interact with these mechanisms – and why you have the absolute right to know about it as a potential treatment for you or someone you love.
Addressing Brain Hypometabolism in Alzheimer’s: Harnessing the Ketogenic Diet
Central to Alzheimer’s pathology is a phenomenon known as brain hypometabolism. Let me explain better what that term means.
Brain hypometabolism refers to a state of reduced metabolic activity in the brain, characterized by a decreased uptake and utilization of glucose – the primary energy source for brain cells. This disastrous metabolic slowdown is not just a mere lack of energy, although that would be devastating enough. It triggers a cascade of detrimental effects that impair neuronal function and disrupts communication between brain cells.
Neurons are highly energy-dependent; even a slight energy deficit can significantly impact their ability to function. Without the ability to utilize glucose for fuel, they become less efficient at transmitting signals, and their ability to form new connections, essential for learning and memory, is compromised. Over time, sustained hypometabolism can lead to the loss of neurons and a subsequent reduction in brain volume (shrinkage of the brain), both of which contribute to cognitive decline and the emergence of symptoms associated with conditions like Alzheimer’s Disease. Hence, brain hypometabolism represents a key factor in the pathogenesis of various neurodegenerative disorders.
Let me be very clear in case that last sentence didn’t hit home for you.
This is not a matter of debate or contention in the scientific community. Brain imaging studies have consistently shown reduced glucose uptake in certain areas of the Alzheimer’s brain. Numerous peer-reviewed studies have linked this diminished metabolic activity to the cognitive decline and memory loss that characterizes Alzheimer’s Disease.
It’s not a hypothetical link or mere correlation but a firmly established aspect of the disease’s pathology. Hence, brain hypometabolism is not a side effect or an outcome of Alzheimer’s; it’s a core part of the disease process itself.
Faced with this irrefutable evidence, targeting brain hypometabolism emerges as an essential, arguably paramount strategy in grappling with Alzheimer’s Disease. Yet, despite its core role in the disease’s progression, brain hypometabolism remains unaddressed by current medications or standard-of-care treatments for Alzheimer’s Disease.
Hypometabolic Brain Structure in AD
As previously mentioned, in AD, this metabolic impairment is particularly evident in specific brain regions critical for memory and cognitive functions. Two regions frequently implicated are the parietal lobe and the posterior cingulate cortex.
The parietal lobe, located near the back of the brain, is responsible for various tasks, including spatial navigation, attention, and language processing. Its impairment can lead to difficulties in performing these tasks, manifesting as getting lost easily, struggling to maintain attention, or having trouble with reading or understanding speech.
The posterior cingulate cortex, found in the middle of the brain, plays a vital role in memory retrieval and cognitive control. Dysfunction in this area can contribute to difficulties in recalling information and making decisions, which are hallmark symptoms of AD.
As the ability of these regions to effectively utilize glucose diminishes, so too does their ability to perform these critical tasks, contributing significantly to the cognitive decline seen in AD.
But I do not want to give you the impression that it is just a couple of areas of the brain that become hypometabolic in Alzheimer’s disease.
In Alzheimer’s Disease, brain hypometabolism isn’t confined to a single area, but rather, it manifests in a progressive manner, affecting various regions over time. While it’s true that the parietal lobe and the posterior cingulate cortex are among the earliest and most severely affected, as the disease progresses, other areas of the brain also experience reduced glucose uptake and utilization.
Notably, the frontal lobe, the seat of our executive functions like decision-making, problem-solving, and emotional control, eventually becomes hypometabolic in the later stages of the disease. This metabolic decline in the frontal lobe can lead to behavioral changes, impaired judgment, and difficulties in carrying out routine tasks.
But the problem of brain hypometabolism doesn’t just stop there.
In Alzheimer’s Disease, brain hypometabolism insidiously spreads beyond the initially affected areas, gradually engulfing virtually the entire cerebral cortex, the brain’s outermost layer tasked with higher-order functions. Of particular significance is the temporal lobe, home to the hippocampus—the brain’s memory epicenter. As metabolic activity dwindles in these regions, symptoms associated with Alzheimer’s, such as memory loss, become increasingly apparent. The pervasiveness of this metabolic disruption underscores the critical importance of combating this issue head-on.
According to a publication from the National Center for Biotechnology Information (NCBI) database, researchers have observed a reduction in glucose utilization in specific regions of the brain, indicating brain hypometabolism. This phenomenon occurs at least 15 years (possibly 30) before severe enough manifestation of symptoms associated with Alzheimer’s disease. While there is potential for utilizing brain imaging and spinal fluid analysis to evaluate the risk of Alzheimer’s disease over a decade or more before the typical manifestation of symptoms, including mild cognitive impairment, don’t expect your doctor to offer this level of testing anytime soon. Currently, the medical establishment does not take your early cognitive symptoms seriously enough to offer them.
Luckily we have the ketogenic diet—literally a metabolic brain therapy.
Inducing a state of ketosis shifts the body’s energy source from glucose to fatty acids, which are broken down into ketone bodies, like beta-hydroxybutyrate and acetoacetate.
Two of these ketones, beta-hydroxybutyrate and acetoacetate, are ridiculously efficient at bypassing dysfunctional glucose metabolism in the brain. They can be swiftly and efficiently taken up by brain cells for fuel, thereby reinvigorating the brain’s energy supply.
Is all this feeling theoretical? No worries. I encourage you to watch this video of a brain literally lighting back up with energy after an infusion of just one of these ketone bodies in a research study.
But you’ve been told brains need glucose! What is going to happen to me or my loved one if we cut carbs that low? Your brain makes all the glucose your body needs through gluconeogenesis, which provides it in just the right amount and schedule. In fact, eating too many carbohydrates may have helped create the problem of brain hypometabolism to begin with.
When you or your loved one restricts your carbohydrate intake for a long enough period, the body will use both the dietary fat you eat and the fat it burns off the body to produce ketones. If someone is malnourished or has a lower weight, it just means we increase dietary fat intake to keep the energy up and minimize the potential for any weight loss.
Since we are talking about brain metabolism and brain energy, I need you to know that ketogenic diets do not just rescue brain energy by providing an alternative fuel source. They are also molecular signaling bodies.
And as that applies to energy, you should know that they turn gene pathways on that allow more mitochondria (power plants of the cells) to be created and also allows the existing powerhouses (mitochondria) to work more efficiently and function better. As you can imagine, this has a lot of beneficial downstream and healing effects for the struggling Alzheimer’s brain struggling with energy production.
And my goodness, wouldn’t just this one effect of ketogenic diets being able to correct brain hypometabolism be such a godsend? Wouldn’t just this one effect be a better treatment all by itself than all the medications we currently use as a standard of care? Yes! It absolutely would. And I would leave this article at that and send you on your way toward your healing (or that of your loved ones). But there are actually additional effects that a ketogenic diet provides that are so instrumental in slowing or stopping Alzheimer’s disease progression. I want you to know them all.
Oxidative Stress in Alzheimer’s Disease: Utilizing Ketogenic Power
Considering impairment of mitochondrial function is a driver of oxidative stress (OS), it should come as no surprise that oxidative stress is part of what drives the disease process in Alzheimer’s disease (AD).
For those new to this term, oxidative stress describes the imbalance that occurs in our bodies between harmful molecules called reactive oxygen species (ROS) and our ability to defend against them. You can’t be alive and not make ROS, as they are a normal part of metabolism, but in the Alzheimer’s brain, oxidative stress goes off the charts, and the brain’s inability to combat it drives disease progression, causing damage to our neurons, proteins, and DNA. This damage is what we refer to as oxidative stress. But what does oxidative stress look like when it is happening in the brain? It looks like lipid peroxidation and protein misfolding.
Oxidative Stress Drivers in Alzheimer’s
Lipid peroxidation is one of the most common outcomes of oxidative stress. It is super destructive to neurons because their plasma membranes contain high amounts of polyunsaturated fatty acids. Polyunsaturated fatty acids are susceptible to oxidation. This process changes the properties of the cell membrane, affecting its fluidity, permeability, and the function of membrane-bound proteins. This tanks crucial neuronal functions and the ability of neurons to communicate with one another.
Protein oxidation leads to the alteration of protein structure and function. This can disrupt enzyme activity and receptor function, inhibiting neurons’ normal biochemical and metabolic processes.
And what do we see in the Alzheimer’s brain, struggling with huge amounts of oxidative stress?
Oxidative stress can exacerbate amyloid-beta production and accumulation. This peptide can induce oxidative stress by itself, creating a vicious cycle of damage. Moreover, oxidatively damaged proteins and lipids are prone to form aggregates, which can exacerbate the formation of amyloid-beta plaques.
The role of oxidative stress is also evident in the hyperphosphorylation of tau, another characteristic of Alzheimer’s. Under conditions of oxidative stress, there is increased activation of several kinases (enzymes that add phosphate groups to other proteins), which can lead to tau hyperphosphorylation. Hyperphosphorylated tau is more prone to aggregation, leading to the formation of neurofibrillary tangles, another hallmark of AD.
Additionally, oxidative stress can lead to neuronal death in AD through a process called apoptosis or programmed cell death. Chronic exposure to oxidative stress can trigger this pathway, leading to the loss of neurons and the worsening of cognitive symptoms.
Let me say that again, in another way, in case that didn’t hit home for you.
Oxidative stress doesn’t merely play a bystander role in Alzheimer’s disease. This is not merely an associational connection found in the scientific literature. Oxidative stress in the Alzheimer’s brain is a powerful and insidious force actively driving the disease’s development and progression. Its unchecked reign triggers and accelerates the brain’s decline, relentlessly exacerbating the degeneration that hallmarks Alzheimer’s disease.
Unchecked oxidative stress drives neurochemical events leading to the formation of Alzheimer’s characteristic hallmarks: amyloid-beta plaques and tau tangles.
Why is oxidative stress unchecked in the Alzheimer’s brain? Because the medications we develop for the disease do not go far enough back in the causational chain to give us anything to hope for. They don’t fix brain energy. They don’t address the cascade of oxidative stress that comes in many cases of Alzheimer’s disease from a crisis of brain energy.
Luckily, we have the ketogenic diet at our disposal to help battle oxidative stress in the Alzheimer’s disease brain.
But what are the mechanisms by which the ketogenic diet accomplishes this?
Ketogenic Diets Reduce Oxidative Stress
First, increasing brain energy and improving mitochondrial number and function which is a part of the ketogenic diet, is a huge boon to fighting oxidative stress. Neurons need the energy to do the basic functioning and housekeeping of cells! How good are you at doing your chores or work when you don’t have energy? Not so good? Things pile up, and stuff is barely accomplished or not done well? Exactly. Your brain needs the rescue of energy that occurs on a ketogenic diet to keep oxidative stress in check and manage the balance between oxidative stress and ROS in the brain.
β-hydroxybutyrate (BHB), a primary ketone body produced during ketosis, has been found to possess antioxidant properties. A reduction in ROS is achieved by enhancing the efficiency of the electron transport chain in mitochondria, reducing electron leakage and, subsequently the formation of ROS. By lowering the overall ROS production, BHB can indirectly reduce the burden of oxidative stress.
But the ketogenic diet has other powerful ways in which it helps reduce oxidative stress. Ketogenic diets have been shown to be able to increase a powerful endogenous (made in our body) antioxidant known as glutathione (GSH).
The increase in glutathione production we see on a ketogenic diet is likely because ketosis promotes the production of NADPH, a coenzyme that plays a vital role in the regeneration of glutathione. When cells have an adequate supply of NADPH, they can more efficiently convert oxidized glutathione (GSSG) back into its reduced, active form (GSH), thereby maintaining a robust antioxidant defense.
By supporting the production and regeneration of glutathione, BHB helps maintain a pool of active, reduced glutathione ready to neutralize ROS and reduces oxidative stress by exhibiting its own independent antioxidant properties. This symbiotic relationship between BHB and glutathione serves to reinforce the antioxidant defenses, particularly important in the brain where oxidative stress can have devastating effects.
Why wouldn’t we use the ketogenic diet as a first-line defense against the ravages of oxidative stress? Why wouldn’t this be a powerful treatment of choice, particularly within the context of the devastatingly insufficient effects on Alzheimer’s disease progression being offered as our current standard of care?
Wouldn’t a rescue of brain energy through an alternative fuel source, increased mitochondrial biogenesis, and improved antioxidant properties to reduce oxidative stress be enough to nominate this metabolic therapy for the brain as treatment of the year for dementias? It would. But believe it or not, there are more pleiotropic effects of a ketogenic diet that you will want to know about.
Neurotransmitter Imbalance in Alzheimer’s: The Keto Effect
Medications that intervene solely at the neurotransmitter balance and function level are, quite frankly, missing the forest for the trees. They are focusing on the end product of a long, cascading process without addressing the upstream dysfunction in the mitochondria, metabolism, and oxidative stress regulation that fuels the pathological progression toward Alzheimer’s disease. But you may be curious about how a ketogenic diet can help with the neurotransmitter issues we see develop in Alzheimer’s, so let’s continue learning!
So let’s go back to reviewing the futility of medications focused on neurotransmitter problems seen in Alzheimer’s disease but also move forward in our understanding of how a ketogenic diet is a superior option to deal with them once they occur.
Keep a Handle on your Glutamate
Remember from your reading earlier in this post that NMDA receptor antagonists like Memantine (Namenda) are drugs prescribed in an attempt to regulate the activity of glutamate. It just so happens the ketogenic diet has powerful effects without the side effects.
Why wouldn’t we leverage a ketogenic diet for this purpose and avoid the side effects of dizziness, headaches, and confusion that are a part of these medications?
Ketogenic Diets Modulate GABA
It’s not all about reducing toxic levels of glutamate, though. There needs to be a balance between the excitatory neurotransmitter glutamate and the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). One of the main effects of a ketogenic diet on brain chemistry involves (GABA), the primary inhibitory neurotransmitter in the brain. Research has shown that ketone bodies can increase the brain’s production of GABA. This is relevant to Alzheimer’s disease because GABAergic signaling is often disturbed in Alzheimer’s patients, and improving GABAergic tone might help restore balance to the neural networks disrupted by the disease.
Also, remember that in the introduction, we discussed the use of a class of medications known as Cholinesterase inhibitors. The purpose of these drugs was to slow down the breakdown of acetylcholine, a neurotransmitter often depleted in Alzheimer’s patients.
But what about Acetylcholine?
Acetylcholine is a neurotransmitter that plays a key role in memory and learning and is notably diminished in Alzheimer’s disease. While the ketogenic diet doesn’t directly increase acetylcholine levels, it supports brain health in a way that helps preserve acetylcholine function. By reducing oxidative stress and supporting mitochondrial function, a ketogenic diet protects cholinergic neurons (neurons that use acetylcholine to transmit signals) from damage.
So knowing that oxidative stress and damaged mitochondria can impair acetylcholine release and receptors, how about we just exponentially improve mitochondrial function and reduce oxidative stress through the powerful mechanisms inherent in a ketogenic diet? I suspect we may see improved acetylcholine levels in Alzheimer’s patients without the common side effects of nausea, vomiting, and diarrhea.
Easing Neuroinflammation in Alzheimer’s Disease: The Therapeutic Impact of Ketosis
Neuroinflammation happens when your immune system is trying to protect your brain from an infection, injury, or abnormal protein accumulation. When the immune response is triggered in the brain, microglia and astrocytes actively attack the threat. And as they attack the threat, they exude and release a bunch of inflammatory cytokines. And just like in a gunfight, some bullets are going to fly around in an unprecise manner, and some collateral damage is going to occur.
If your oxidative stress levels are well managed, the brain can rebuild and repair from this process; if not, it doesn’t. And in this way, neuroinflammation helps drive neurodegenerative processes.
When neuroinflammation becomes chronic and unrelenting, it will literally change how these microglia behave (morphology) and make them quite “trigger happy” and aggressive in their behavior around dealing with assaults. When in this overactive state, microglia will begin to eat and destroy neurons that were only sick and could have been saved!
You can imagine how a poorly functioning immune system, broken blood-brain barrier (BBB) unable to protect the brain, or high levels of oxidative stress due to glucose hypometabolism (poor brain energy) or micronutrient insufficiencies can all drive a nonstop cascade of neuroinflammation. And unsurprisingly, it can contribute to the development and progression of neurodegenerative diseases, including Alzheimer’s disease.
If you are still feeling a little confused about the differences between neuroinflammation and oxidative stress and how they are related, you may find this article below helpful.
Before we go into the mechanisms by which a ketogenic diet reduces neuroinflammation, let’s review our understanding thus far.
Ketones fuel brains and rescue brain energy. If a brain is starving for energy, it becomes stressed and excitatory. Oxidative stress goes through the roof, and micronutrients become depleted trying to keep things in check. Neurotransmitters become imbalanced (and neurotoxic in their imbalance; remember Glutamate?), and their neurotransmitter receptors break and disrupt communication pathways required for upkeep and function. Neuroinflammation occurs and is generated through a nonstop feedback loop and reaches a chronic state in the brain.
We have also learned that ketone bodies can boost the brain’s antioxidant capacity directly and indirectly. And if that was, were the benefits of a ketogenic diet stopped? If that was “all” a ketogenic diet could offer a neurodegenerative brain process like Alzheimer’s disease, wouldn’t that be enough? Wouldn’t we be just so relieved that there was something to help all of those disease mechanisms improve?
We would! And we are! But those are not the only ways in which a ketogenic diet helps fight neuroinflammation. This blog post could stop there. But I really want you to understand the multitude of pleiotropic effects the ketogenic diet has on brain health, so I can finally get it through everyone’s heads that we don’t have medications that do even a fraction of this!
Taming Microglia: The Ketogenic Diet’s Unseen Neurological Benefit
As discussed earlier, microglial cells play a critical role in neuroinflammation.
Keto: The Master Regulator of Inflammatory Pathways
There are a lot of different mechanisms by which a ketogenic diet fights inflammation, and it’s effects as a molecular signaling body on different inflammatory pathways is truly one of the most impressive of them all!
Ketogenic diet’s effects on NLRP3 inflammasome
First, BHB (one of those ketone bodies made on a ketogenic diet) inhibits something called the NLRP3 inflammasome. This is a protein complex that plays a crucial role in the innate immune response and inflammation. When activated by microglia and other cell types, it triggers the release of pro-inflammatory cytokines like IL-1β and IL-18, which contribute to inflammatory processes in the body.
Ketogenic diets play a role in inhibiting this process. By inhibiting the NLRP3 inflammasome, BHB helps reduce the release of pro-inflammatory cytokines and dampen the inflammatory response.
BHB can inhibit the NLRP3 inflammasome by multiple mechanisms. It inhibits the assembly of the NLRP3 inflammasome complex, preventing its activation. It inhibits the production of pro-inflammatory cytokines like IL-1β by reducing the activation of the inflammasome. And it can modulate the activity of the transcription factor NF-κB, which regulates the expression of genes involved in inflammation.
Let’s read that last sentence again. It regulates the expression of genes involved in inflammation. Show me a pharma drug for Alzheimer’s that successfully does that.
Ketogenic keys to HCA2
Another role played by beta-hydroxybutyrate (BHB), a ketone produced on a ketogenic diet, is its interaction with a receptor called Hydroxycarboxylic Acid Receptor 2 (HCA2) or G-protein coupled receptor 109A (GPR109A). This ketone body binds and activates HCA2 and sends a signal within the cell to reduce inflammation.
Now, let’s talk about prostaglandins. Prostaglandins are chemicals in our bodies that play a role in inflammation. They act like messengers that carry signals to cells, telling them to become inflamed. BHB reduces the production of these prostaglandins. When BHB activates HCA2, it sends a signal to cells to stop sending those inflammatory text messages. In other words, BHB acts as a “mute” button for the cells, preventing them from releasing too many messages that promote inflammation.
By reducing the production of prostaglandins and dampening the inflammatory response, BHB helps to control inflammation in the body. This is one way the ketogenic diet, with its increased production of BHB, can have anti-inflammatory effects.
Ketogenic Diet: A Gut-Brain Axis Transformer for Combating Inflammation
The gut microbiome is thought to exert an influence on Alzheimer’s disease progression. It is thought to do this via microbiome production of metabolites, effects on neurotransmitters, modulation of the immune system and inflammation, and potential effects on the integrity of the blood-brain barrier (BBB).
The ketogenic diet leads to significant changes in the gut microbiome. It promotes the growth of beneficial bacteria while reducing the abundance of potentially harmful microbes. This shift in the microbial composition is seen to impact brain function and inflammation through the gut-brain axis profoundly.
Why? Because the gut microbiome produces various metabolites and signaling molecules that can interact with the nervous system. These molecules can directly affect brain function and modulate inflammatory processes. The ketogenic diet’s ability to reduce inflammation could be mediated, at least in part, by its impact on the gut microbiota. It’s just one more mechanism by which a ketogenic diet helps fight neuroinflammation and modulates just one more underlying disease process seen in Alzheimer’s dementia.
Why wouldn’t we use an intervention that promotes a healthier inflammatory state in the brain in someone suffering from a neurodegenerative process like Alzheimer’s disease?
If you want to understand the ketogenic diet’s effects on some of the other factors related to the microbiome discussed in this section, please see these additional articles below before moving on to the conclusion.
In Conclusion: Alzheimer’s Disease and the Indispensable Role of the Ketogenic Diet
So will a ketogenic diet fix all the underlying pathological mechanisms that are a part of your loved ones (or your) cognitive decline? Possibly. But possibly not. If oxidative stress is being further driven by heavy metal burden, exposure to mold toxicity, hidden infections, or a variety of other factors, you will likely want or need some additional help. Disease progression could be driven by insufficient or deficient levels of important micronutrients that mitochondria need to thrive (blog post coming soon).
There are different driving factors for Alzheimer’s disease and different phenotypes. The purpose of this article is not to argue or debate whether a ketogenic diet will fix all the underlying pathological mechanisms that are a part of anyone’s particular disease progression.
The point and purpose of this article are to point out to you that a ketogenic diet is the most comprehensive and neuroprotective treatment option we have. To effectively communicate to you that if anything has the chance to stop or slow the progression of Alzheimer’s disease through multiple complementary mechanisms, it is, quite frankly, the ketogenic diet.
And finally, this article was written to hopefully shatter the misconception that the treatments prescribed by your neurologist represent the sole avenues for dealing with what has been inaccurately portrayed as a dire and irreversible prognosis. I am not sure that is the case when these underlying factors described in this post are given access to a powerful intervention like the ketogenic diet. At the very least, in many cases, I think a slowing of the progression is possible.
Don’t sit idly by, waiting for healthcare professionals to catch up with the pace of scientific discovery while your brain or a loved one continues to neurodegenerate to a point of no return.
You can work with a ketogenic-trained dietician or nutritionist to help them (or yourself). If you have early Mild Cognitive Impairment (MCI) or later-stage Alzheimer’s and have the support of a caregiver, you may find support and benefit in my online program.
Regardless of where you decide to go for help, don’t wait.
I am here to tell you no one is going to rescue you or your loved one from the jaws of dementia. The action of implementing a ketogenic diet is doable, and there is so much support out there.
I send you love on your journey.
If you are looking for information about exogenous ketones you may find the following articles helpful.
Achanta, L. B., & Rae, C. D. (2017). β-Hydroxybutyrate in the Brain: One Molecule, Multiple Mechanisms. Neurochemical Research, 42(1), 35–49. https://doi.org/10.1007/s11064-016-2099-2
Almulla, A. F., Supasitthumrong, T., Amrapala, A., Tunvirachaisakul, C., Jaleel, A.-K. K. A., Oxenkrug, G., Al-Hakeim, H. K., & Maes, M. (2022). The Tryptophan Catabolite or Kynurenine Pathway in Alzheimer’s Disease: A Systematic Review and Meta-Analysis. Journal of Alzheimer’s Disease, 88(4), 1325–1339. https://doi.org/10.3233/JAD-220295
Altayyar, M., Nasser, J. A., Thomopoulos, D., & Bruneau, M. (2022). The Implication of Physiological Ketosis on The Cognitive Brain: A Narrative Review. Nutrients, 14(3), Article 3. https://doi.org/10.3390/nu14030513
Alves, F., Kalinowski, P., & Ayton, S. (2023). Accelerated Brain Volume Loss Caused by Anti–β-Amyloid Drugs: A Systematic Review and Meta-analysis. Neurology, 100(20), e2114–e2124. https://doi.org/10.1212/WNL.0000000000207156
Alzheimer’s Symptoms: Brain Changes. (n.d.). Retrieved May 21, 2023, from https://www.healthline.com/health-news/can-alzheimers-be-detected-30-years-before-it-appears
Ardanaz, C. G., Ramírez, M. J., & Solas, M. (2022). Brain Metabolic Alterations in Alzheimer’s Disease. International Journal of Molecular Sciences, 23(7), Article 7. https://doi.org/10.3390/ijms23073785
Bohnen, J. L. B., Albin, R. L., & Bohnen, N. I. (2023). Ketogenic interventions in mild cognitive impairment, Alzheimer’s disease, and Parkinson’s disease: A systematic review and critical appraisal. Frontiers in Neurology, 14, 1123290. https://doi.org/10.3389/fneur.2023.1123290
Costantini, L. C., Barr, L. J., Vogel, J. L., & Henderson, S. T. (2008). Hypometabolism as a therapeutic target in Alzheimer’s disease. BMC Neuroscience, 9(Suppl 2), S16. https://doi.org/10.1186/1471-2202-9-S2-S16
Croteau, E., Castellano, C. A., Fortier, M., Bocti, C., Fulop, T., Paquet, N., & Cunnane, S. C. (2018). A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer’s disease. Experimental Gerontology, 107, 18–26. https://doi.org/10.1016/j.exger.2017.07.004
Cullingford, T. E. (2004). The ketogenic diet; fatty acids, fatty acid-activated receptors and neurological disorders. Prostaglandins, Leukotrienes and Essential Fatty Acids, 70(3), 253–264. https://doi.org/10.1016/j.plefa.2003.09.008
Cunnane, S., Nugent, S., Roy, M., Courchesne-Loyer, A., Croteau, E., Tremblay, S., Castellano, A., Pifferi, F., Bocti, C., Paquet, N., Begdouri, H., Bentourkia, M., Turcotte, E., Allard, M., Barberger-Gateau, P., Fulop, T., & Rapoport, S. (2011). BRAIN FUEL METABOLISM, AGING AND ALZHEIMER’S DISEASE. Nutrition (Burbank, Los Angeles County, Calif.), 27(1), 3–20. https://doi.org/10.1016/j.nut.2010.07.021
Dilliraj, L. N., Schiuma, G., Lara, D., Strazzabosco, G., Clement, J., Giovannini, P., Trapella, C., Narducci, M., & Rizzo, R. (2022). The Evolution of Ketosis: Potential Impact on Clinical Conditions. Nutrients, 14(17), Article 17. https://doi.org/10.3390/nu14173613
Gano, L. B., Patel, M., & Rho, J. M. (2014). Ketogenic diets, mitochondria, and neurological diseases. Journal of Lipid Research, 55(11), 2211–2228. https://doi.org/10.1194/jlr.R048975
Gómora-García, J. C., Montiel, T., Hüttenrauch, M., Salcido-Gómez, A., García-Velázquez, L., Ramiro-Cortés, Y., Gomora, J. C., Castro-Obregón, S., & Massieu, L. (2023). Effect of the Ketone Body, D-β-Hydroxybutyrate, on Sirtuin2-Mediated Regulation of Mitochondrial Quality Control and the Autophagy–Lysosomal Pathway. Cells, 12(3), Article 3. https://doi.org/10.3390/cells12030486
Grammatikopoulou, M. G., Goulis, D. G., Gkiouras, K., Theodoridis, X., Gkouskou, K. K., Evangeliou, A., Dardiotis, E., & Bogdanos, D. P. (2020). To Keto or Not to Keto? A Systematic Review of Randomized Controlled Trials Assessing the Effects of Ketogenic Therapy on Alzheimer Disease. Advances in Nutrition, 11(6), 1583–1602. https://doi.org/10.1093/advances/nmaa073
Jarrett, S. G., Milder, J. B., Liang, L.-P., & Patel, M. (2008). The ketogenic diet increases mitochondrial glutathione levels. Journal of Neurochemistry, 106(3), 1044–1051. https://doi.org/10.1111/j.1471-4159.2008.05460.x
Jiang, Z., Yin, X., Wang, M., Chen, T., Wang, Y., Gao, Z., & Wang, Z. (2022). Effects of Ketogenic Diet on Neuroinflammation in Neurodegenerative Diseases. Aging and Disease, 13(4), 1146. https://doi.org/10.14336/AD.2021.1217
Kalani, K., Chaturvedi, P., Chaturvedi, P., Kumar Verma, V., Lal, N., Awasthi, S. K., & Kalani, A. (2023). Mitochondrial mechanisms in Alzheimer’s disease: Quest for therapeutics. Drug Discovery Today, 28(5), 103547. https://doi.org/10.1016/j.drudis.2023.103547
Kashiwaya, Y., Takeshima, T., Mori, N., Nakashima, K., Clarke, K., & Veech, R. L. (2000). D-β-Hydroxybutyrate protects neurons in models of Alzheimer’s and Parkinson’s disease. Proceedings of the National Academy of Sciences, 97(10), 5440–5444. https://doi.org/10.1073/pnas.97.10.5440
Ketogenic diet ameliorates cognitive impairment and neuroinflammation in a mouse model of Alzheimer’s disease—Xu—2022—CNS Neuroscience & Therapeutics—Wiley Online Library. (n.d.). Retrieved May 24, 2023, from https://onlinelibrary.wiley.com/doi/10.1111/cns.13779
Koh, S., Dupuis, N., & Auvin, S. (2020). Ketogenic diet and Neuroinflammation. Epilepsy Research, 167, 106454. https://doi.org/10.1016/j.eplepsyres.2020.106454
Kong, G., Wang, J., Li, R., Huang, Z., & Wang, L. (2022). Ketogenic diet ameliorates inflammation by inhibiting the NLRP3 inflammasome in osteoarthritis. Arthritis Research & Therapy, 24, 113. https://doi.org/10.1186/s13075-022-02802-0
Kumar, A., Sharma, M., Su, Y., Singh, S., Hsu, F.-C., Neth, B. J., Register, T. C., Blennow, K., Zetterberg, H., Craft, S., & Deep, G. (2022). Small extracellular vesicles in plasma reveal molecular effects of modified Mediterranean-ketogenic diet in participants with mild cognitive impairment. Brain Communications, 4(6), fcac262. https://doi.org/10.1093/braincomms/fcac262
Lilamand, M., Mouton-Liger, F., & Paquet, C. (2021). Ketogenic diet therapy in Alzheimer’s disease: An updated review. Current Opinion in Clinical Nutrition & Metabolic Care, Publish Ahead of Print. https://doi.org/10.1097/MCO.0000000000000759
Macdonald, R., Barnes, K., Hastings, C., & Mortiboys, H. (2018). Mitochondrial abnormalities in Parkinson’s disease and Alzheimer’s disease: Can mitochondria be targeted therapeutically? Biochemical Society Transactions, 46(4), 891–909. https://doi.org/10.1042/BST20170501
Mentzelou, M.; Dakanalis, A.; Vasios, G.K.; Gialeli, M.; Papadopoulou, S.K.; Giaginis, C. The Relationship of Ketogenic Diet with Neurodegenerative and Psychiatric Diseases: A Scoping Review from Basic Research to Clinical Practice. Nutrients 2023, 15, 2270. https://doi.org/10.3390/nu15102270
Milder, J., & Patel, M. (2012). Modulation of oxidative stress and mitochondrial function by the ketogenic diet. Epilepsy Research, 100(3), 295–303. https://doi.org/10.1016/j.eplepsyres.2011.09.021
Mitochondrial dysfunction in human pathologies | DIGITAL.CSIC. (n.d.). Retrieved May 24, 2023, from https://digital.csic.es/handle/10261/152309
Murakami, M., & Tognini, P. (2022). Molecular Mechanisms Underlying the Bioactive Properties of a Ketogenic Diet. Nutrients, 14(4), Article 4. https://doi.org/10.3390/nu14040782
Napolitano, A., Longo, D., Lucignani, M., Pasquini, L., Rossi-Espagnet, M. C., Lucignani, G., Maiorana, A., Elia, D., De Liso, P., Dionisi-Vici, C., & Cusmai, R. (2020). The Ketogenic Diet Increases In Vivo Glutathione Levels in Patients with Epilepsy. Metabolites, 10(12), Article 12. https://doi.org/10.3390/metabo10120504
Pflanz, N. C., Daszkowski, A. W., James, K. A., & Mihic, S. J. (2019). Ketone body modulation of ligand-gated ion channels. Neuropharmacology, 148, 21–30. https://doi.org/10.1016/j.neuropharm.2018.12.013
Pietrzak, D., Kasperek, K., Rękawek, P., & Piątkowska-Chmiel, I. (2022a). The Therapeutic Role of Ketogenic Diet in Neurological Disorders. Nutrients, 14(9), Article 9. https://doi.org/10.3390/nu14091952
Pietrzak, D., Kasperek, K., Rękawek, P., & Piątkowska-Chmiel, I. (2022b). The Therapeutic Role of Ketogenic Diet in Neurological Disorders. Nutrients, 14(9), 1952. https://doi.org/10.3390/nu14091952
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022). ApoE in Alzheimer’s disease: Pathophysiology and therapeutic strategies. Molecular Neurodegeneration, 17(1), 72. https://doi.org/10.1186/s13024-022-00574-4
Rho, J., & Stafstrom, C. (2012). The Ketogenic Diet as a Treatment Paradigm for Diverse Neurological Disorders. Frontiers in Pharmacology, 3. https://www.frontiersin.org/articles/10.3389/fphar.2012.00059
Ribarič, S. (2023). Detecting Early Cognitive Decline in Alzheimer’s Disease with Brain Synaptic Structural and Functional Evaluation. Biomedicines, 11(2), Article 2. https://doi.org/10.3390/biomedicines11020355
Schain, M., & Kreisl, W. C. (2017). Neuroinflammation in Neurodegenerative Disorders—A Review. Current Neurology and Neuroscience Reports, 17(3), 25. https://doi.org/10.1007/s11910-017-0733-2
Sharma, C., & Kim, S. R. (2021). Linking Oxidative Stress and Proteinopathy in Alzheimer’s Disease. Antioxidants, 10(8), Article 8. https://doi.org/10.3390/antiox10081231
Şimşek, H., & Uçar, A. (2022). Is Ketogenic Diet Therapy a Remedy for Alzheimer’s Disease or Mild Cognitive Impairments?: A Narrative Review of Randomized Controlled Trials. Advances in Gerontology, 12(2), 200–208. https://doi.org/10.1134/S2079057022020175
Simunkova, M., Alwasel, S. H., Alhazza, I. M., Jomova, K., Kollar, V., Rusko, M., & Valko, M. (2019). Management of oxidative stress and other pathologies in Alzheimer’s disease. Archives of Toxicology, 93(9), 2491–2513. https://doi.org/10.1007/s00204-019-02538-y
Sridharan, B., & Lee, M.-J. (2022). Ketogenic Diet: A Promising Neuroprotective Composition for Managing Alzheimer’s Diseases and its Pathological Mechanisms. Current Molecular Medicine, 22(7), 640–656. https://doi.org/10.2174/1566524021666211004104703
Strope, T. A., & Wilkins, H. M. (2023). Amyloid precursor protein and mitochondria. Current Opinion in Neurobiology, 78, 102651. https://doi.org/10.1016/j.conb.2022.102651
Thakur, S., Dhapola, R., Sarma, P., Medhi, B., & Reddy, D. H. (2023). Neuroinflammation in Alzheimer’s Disease: Current Progress in Molecular Signaling and Therapeutics. Inflammation, 46(1), 1–17. https://doi.org/10.1007/s10753-022-01721-1
Varesi, A., Pierella, E., Romeo, M., Piccini, G. B., Alfano, C., Bjørklund, G., Oppong, A., Ricevuti, G., Esposito, C., Chirumbolo, S., & Pascale, A. (2022). The Potential Role of Gut Microbiota in Alzheimer’s Disease: From Diagnosis to Treatment. Nutrients, 14(3), 668. https://doi.org/10.3390/nu14030668
Vascular Dementia Lifestyle and Nutrition Prevention Strategies—ProQuest. (n.d.). Retrieved January 27, 2022, from https://www.proquest.com/openview/44d6b91873db89a2ab8b1fbe2145c306/1?pq-origsite=gscholar&cbl=18750&diss=y
Wang, J.-H., Guo, L., Wang, S., Yu, N.-W., & Guo, F.-Q. (2022). The potential pharmacological mechanisms of β-hydroxybutyrate for improving cognitive functions. Current Opinion in Pharmacology, 62, 15–22. https://doi.org/10.1016/j.coph.2021.10.005
Warren, C. E., Saito, E. R., & Bikman, B. T. (n.d.). A Ketogenic Diet Enhances Hippocampal Mitochondrial Efficiency. 2.
Xu, Y., Zheng, F., Zhong, Q., & Zhu, Y. (2023). Ketogenic Diet as a Promising Non-Drug Intervention for Alzheimer’s Disease: Mechanisms and Clinical Implications. Journal of Alzheimer’s Disease, 92(4), 1173–1198. https://doi.org/10.3233/JAD-230002
Yassine, H. N., Self, W., Kerman, B. E., Santoni, G., Navalpur Shanmugam, N., Abdullah, L., Golden, L. R., Fonteh, A. N., Harrington, M. G., Gräff, J., Gibson, G. E., Kalaria, R., Luchsinger, J. A., Feldman, H. H., Swerdlow, R. H., Johnson, L. A., Albensi, B. C., Zlokovic, B. V., Tanzi, R., … Bowman, G. L. (2023). Nutritional metabolism and cerebral bioenergetics in Alzheimer’s disease and related dementias. Alzheimer’s & Dementia, 19(3), 1041–1066. https://doi.org/10.1002/alz.12845
Yin, J. X., Maalouf, M., Han, P., Zhao, M., Gao, M., Dharshaun, T., Ryan, C., Whitelegge, J., Wu, J., Eisenberg, D., Reiman, E. M., Schweizer, F. E., & Shi, J. (2016). Ketones block amyloid entry and improve cognition in an Alzheimer’s model. Neurobiology of Aging, 39, 25–37. https://doi.org/10.1016/j.neurobiolaging.2015.11.018
Younes, L., Albert, M., Moghekar, A., Soldan, A., Pettigrew, C., & Miller, M. I. (2019). Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease. Frontiers in Aging Neuroscience, 11. https://www.frontiersin.org/articles/10.3389/fnagi.2019.00074
Yudkoff, M., Daikhin, Y., Nissim, I., Lazarow, A., & Nissim, I. (2004). Ketogenic diet, brain glutamate metabolism and seizure control. Prostaglandins, Leukotrienes and Essential Fatty Acids, 70(3), 277–285. https://doi.org/10.1016/j.plefa.2003.07.005
Zhu, H., Bi, D., Zhang, Y., Kong, C., Du, J., Wu, X., Wei, Q., & Qin, H. (2022). Ketogenic diet for human diseases: The underlying mechanisms and potential for clinical implementations. Signal Transduction and Targeted Therapy, 7(1), Article 1. https://doi.org/10.1038/s41392-021-00831-w